Predictive value of tumor mutational burden for PD-1/PD-L1 inhibitors in NSCLC: A meta-analysis.

Li, Wenjie; Zhao, Yanjun; Zhang, Hongjun; Zheng, Wenying; Wang, Ruixuan; Gu, Xing

Li, Wenjie; Zhao, Yanjun; Zhang, Hongjun; Zheng, Wenying; Wang, Ruixuan; Gu, Xing.

Affiliation

Li W; Department of Respiratory and Critical Care Medicine, Xi'an Chest Hospital, Chang'an District, Xi'an, Shanxi, China.

Medicine (Baltimore) ; 102(40): e34990, 2023 Oct 06.

Article in En | MEDLINE | ID: mdl-37800825

Subject(s)

Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Humans; Carcinoma, Non-Small-Cell Lung/drug therapy; Carcinoma, Non-Small-Cell Lung/genetics; Immune Checkpoint Inhibitors/therapeutic use; Lung Neoplasms/drug therapy; Lung Neoplasms/genetics; Programmed Cell Death 1 Receptor/therapeutic use; Mutation; Biomarkers, Tumor; B7-H1 Antigen/therapeutic use

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Non-Small-Cell Lung / Lung Neoplasms Type of study: Clinical_trials / Prognostic_studies / Risk_factors_studies / Systematic_reviews Limits: Humans Language: En Journal: Medicine (Baltimore) Year: 2023 Type: Article Affiliation country: China

Fulltext

XML

PubMed Links

Search on Google